Important pharmacy news and late-breaking industry information updated daily.
Study in JAMA Internal Medicine: Industry pays $9 million
President Trump vowed on Friday to "bring soaring drug prices back down to earth" by promoting competition among pharmaceutical companies, but he dropped the proposals of his presidential campaign, deciding not to have the federal government directly negotiate lower drug prices for Medicare.
FDA has issued four new warning letters to manufacturers and retailers for selling e-liquids used in e-cigarettes with labeling and/or advertising that resembles child-friendly food products. One of the companies that received a warning letter was also cited for illegally selling the product to a minor.
FDA on Wednesday said the EpiPen emergency treatment for allergic reactions is in short supply in the United States because of manufacturing delays. Mylan, which sells EpiPens that are manufactured at a Pfizer plant, said some pharmacies lacked supply, but patients could find the drug at other pharmacies.
George Barrett, executive chairman of Cardinal Health, apologized Tuesday for the company’s role in facilitating the flow of highly addictive analgesics into U.S. communities, the first time a corporation has expressed regret for involvement in the opioid crisis.
Pharmacists have opportunities to help patients who take DPP-4 inhibitors
Fred's Inc. announced Monday that it has reached a definitive agreement to sell certain assets of its EntrustRx specialty pharmacy unit to a subsidiary of CVS Health. The unit will be sold for $40 million "plus an amount equal to the value of inventory of EntrustRx," Fred's said.
FDA has approved dabrafenib (Tafinlar—Novartis) and trametinib (Mekinist—Novartis), administered together, for the treatment of anaplastic thyroid cancer (ATC) that cannot be removed by surgery or has spread to other parts of the body, and has a type of abnormal gene, BRAF V600E (BRAF V600E mutation-positive).
Here’s everything pharmacists need to know to help patients with sun care needs this season
FDA Commissioner Scott Gottlieb on Thursday signaled that a federal law on kickbacks could be reinterpreted by the government to help lower the prices of prescription drugs. Drug companies are currently being sued by lawyers who assert that the system of rebates that flow between PBMs, drug manufacturers, and insurers are actually kickbacks.